Synergistic effect of regenerating agent plus cord blood serum eye drops for the treatment of resistant XXXX : a case report and a hypothesis for pathophysiologic mechanism.

@entity1 @entity32 @entity2687 @entity1036
UNASSIGNED: This report describes a case of a 72-year-old Caucasian @entity1 presenting with a large @entity1036 with a large persistent epithelial defect, with a longest linear diameter of 7 mm and greatest perpendicular width of 5 mm, affecting epithelium, Bowman membrane, and anterior stroma. @entity2687 was resistant to conventional treatment and classified as stage 2 according to Mackie classification. @entity1 was instructed to instill regenerating agent (RGTA) eye drops in the morning, as the first eye drop, once every 5 days in combination with daily cord blood serum (CBS) eye drops 6 times/day. The @entity1 was asked to visit after 1 week (V1), 2 weeks (V2), 3 weeks (V3), and 4 weeks (V4) of study treatment. In V4 treatment, corneal sensitivity improved, and @entity1036 healed with resolution of stromal @entity32 . Global treatment tolerance was very satisfactory. @entity1 continued the therapy for a further month after complete healing. Currently, the @entity1 has been followed up for 3 months without any sign of @entity1036 recurrence. To the best of our knowledge, this case report describes for the first time the successful combined use of RGTA and CBS eye drops for the treatment of @entity1036 resistant to conventional treatment. We hypothesize that RGTA eye drops could provide an optimal migration substrate and that growth factors supplied by CBS eye drops could strengthen the repair process by promoting cell growth over the matrix. Combined RGTA and CBS eye drop therapy could be a new potential option for the successful treatment of resistant @entity1036 , particularly when each drug alone is not effective.
